REFERENCES
- Shuchat A. Group B streptococcus. Lancet 1999; 353: 51–56.
- Heelan JS, Hasenbein ME, McAdam AJ. Resistance of group B Streptococcus to selected antibiotics, including eryth-romycin and clindamycin. J Clin Microbiol 2004; 42: 1263–1264.
- Kawamura Y, Fujiwara H, Mishima N et al. First Strepto-coccus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother 2003; 47: 3605–3609.
- Wehbeh W, Rojas-Diaz R, Li X et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 2005; 49: 2495–2497.
- Wu HM, Janapatla RP, Ho YR, Hung KH, Wu CW, Yan JJ, Wu JJ. Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. Antimicrob Agents Chemother 2008; 52: 1880–1890.
- Miro E, Rebollo M, Rivera A et al. Streptococcus agalac-tiae highly resistant to fluoroquinolones. Enferm Infecc Microbiol Clin 2006; 24: 562–563.
- Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: approved standard. 7th ed. CLSI document M7-A7. Clinical Lab-oratory Standards Institute, Wayne, P.A, 2006.
- Clinical Laboratory Standards Institute. Performance stan-dards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-518. Clinical Laboratory Standards Institute, Wayne, P.A, 2008.
- Rivera A, Rebollo M, Sanchez F et al. Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyo-genes in Barcelona, Spain. Clin Microbiol Infect 2005; 11: 759–761.
- Tazi A, Gueudet T, Varon E et al. Fluoroquinolone-resis-tant group B streptococci in acute exacerbation of chronic bron-chitis. Emerg Infect Dis 2008; 14: 349–350.
- Perez-Trallero E, Marimon JM, Gonzalez A et al. In vivo development of high-level fluoroquinolone resistance in Strep-tococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41: 560–564.